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Objective: Sweet’s syndrome (SS) is characterized by various clinical symptoms, physical features, and pathological
findings. Although cases of SS are very rare, there has been an increase in the incidence of drug-induced SS. Till
date, there have been only few reported cases of isotretinoin-induced SS.
Case summary: In this report, we describe the case of a 19-year-old girl who developed SS after systemic treatment
with oral isotretinoin for nodulocystic acne.
Conclusions: The findings of this report emphasize the importance of evaluating isotretinoin as a possible, though
uncommon, cause of SS and replacing it with another treatment if its involvement is suspected.
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Sweet’s syndrome (SS) is characterized by painful
erythematous skin lesions due to neutrophil infiltration in
the upper dermis, fever, leukocytosis with a predominance
of neutrophils, and increased erythrocyte sedimentation
rate (ESR) [1,2]. There are three clinical forms of SS:
classical (idiopathic), malignancy associated, and drug
induced [3]. Classical SS usually develops in women aged
between 30 and 40 years and is often preceded by upper
respiratory or gastrointestinal tract infection, inflammatory
bowel disease, and pregnancy. Malignancy-associated SS
can occur as a paraneoplastic syndrome. Drug-induced SS
most commonly occurs in patients who have been treated
with granulocyte colony-stimulating factor [3]. Although this
form of SS is very rare, there has been an increase in the
incidence of drug-induced SS [4]. Here we describe the case
of a 19-year-old girl who developed drug-induced SS after
systemic treatment with oral isotretinoin (13-cis-retinoic
acid) for nodulocystic acne and emphasize the importance
of evaluating isotretinoin as a possible, though uncommon,
cause of SS.* Correspondence: m.pourazizi@yahoo.com
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A 19-year-old girl presented to the rheumatology clinic
because of malaise, polyarthralgia, and weight loss (5 kg),
which she experienced during six months before presenta-
tion to the clinic. She did not have any fever during presen-
tation to the clinic. During two weeks before presentation
to the clinic, she developed very painful and tender skin
lesions on her legs and in the suprapubic area. Her medical
history was insignificant. She had no history of inflamma-
tory bowel disease or rheumatological disease. She did not
have symptoms indicative of contact dermatitis or any
history of drug intake, except for the use of isotretinoin for
severe facial acne vulgaris, which was initiated one year ago
at a dose of 20 mg twice daily and was tapered gradually to
a dose of 20 mg weekly. A similar lesion appeared 1 month
after the initiation of isotretinoin therapy. These lesions
resolved without intervention. However, the lesions at the
time of presentation to the clinic were more severe and
painful, and the patient was admitted to the hospital for
clinical evaluation. Physical examination showed that she
was unnaturally thin and that she looked ill. Her vital signs
were not remarkable, and she did not have fever, lymph-
adenopathy, hepatosplenomegaly, and other symptoms.
Dermatological examination showed tender erythematous
plaques with pustules and crust on the ventromedial
aspects of her mid-thighs, suprapubic region, and right calf
[Figure 1]. Initial laboratory examination determined
leukocytosis (23100 cells/mm3) and neutrophilia (65%).al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Isotretinoin-associated Sweet’s Syndrome. Erythematous, edematous, painful plaques on suprapubic area (A) and right lower extremity (B).
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O titers were negative. Her ESR was >100. Antineutrophil
cytoplasmic antibody and antinuclear antibody titers and
blood, wound, and urine cultures were negative. Tubercu-
losis skin test (PPD skin test) provided insignificant
results. Kidney and liver function tests, urine analysis,
echocardiography, chest radiography, and total abdomino-
pelvic sonography yielded normal results. Bone marrow
aspiration and biopsy yielded normal results. Therefore,
hematological and solid organ malignancies were ruled
out. Skin punch biopsy from a new, well-developed lesion
showed spongiotic epidermis with mild dermal edema.
Massive aggregates of neutrophils were observed in the
upper and mid-dermis, but there was no obvious sign of
vasculitis [Figure 2]. Thus, the patient was diagnosed as
having drug-induced SS due to isotretinoin based on the
above observations and criteria for SS. Isotretinoin therapy
was stopped, and prednisolone therapy was initiated at aFigure 2 Isotretinoin-associated Sweet’s Syndrome. Edema of
dermis, infiltration of neutrophils and leukocytoclasis, edema of
endothelial cells and no vasculitis.dose of 60 mg/day (1 mg/kg). Dose tapering was initiated
after 2 weeks; after 6 weeks, the dose was tapered to
5 mg/day. Complete resolution of the lesions was
observed within 4 weeks. The patient was advised to avoid
isotretinoin and asked to return for follow-ups.Ethical approval
This is a report of rare case, however the report was
approved by the Ethics Committee of Semnan University
of Medical Sciences, Semnan, Iran.Conclusions
Etiologically, SS may be associated with drugs, infections,
and paraneoplastic or inflammatory conditions such as
inflammatory bowel diseases and rheumatological diseases.
When no triggering factor is detected, the disease is catego-
rized as classic or idiopathic [4].
Only few cases of SS have been reported to be caused by
drug reactions. Drug-induced SS is rare and probably
represents <5% of all cases [5]. The clinical presentation
and histology of drug-induced SS are similar to those of
idiopathic SS [6]. Neutrophilia is often absent in drug-
induced SS probably because many of these cases are
caused by the use of hematopoietic growth factors that are
used for reversing chemotherapy-induced neutropenia.
Lesions in drug-induced SS usually develop approximately
one week after the initiation of the drug [7]. After with-
drawing the causative drug, fever abates in 1–3 days and
lesions disappear within 3–30 days [5]. Systemic cortico-
steroids may be required in severe cases. Drugs associated
with drug-induced SS include all-trans-retinoic acid and
G-CSF or GM-CSF [5]. Some cases may be attributed to
trimethoprim/sulfamethoxazole, norfloxacin, furosemide,
celecoxib, tetracyclines, and antiepileptic drugs [4,7].
Other implicated drugs are summarized in Table 1 [4].
Table 1 Drugs reported as inducing Sweet’s syndrome
Granulocytes growth factors G-CSF (granulocyte-colony stimulating factor); GM-CSF (granulocyte monocyte colony stimulating factor);
All trans-retinoic acid
Vaccination Calmette-Guérin; Influenza; Streptococcus pneumonia; Small-pox
Antibiotics Doxycycin; Cyclines (minocycline, tetracycline and doxycycline); Quinolones: norfloxacin, ofloxacin; Nitrofurantoin;
Streptogramin (quinupristin/dalfopristin); Trimethoprim-sulphamethoxazole
Antivirals Abacavir; Acyclovir
Anti-tumoural biotherapies Proteasomes inhibitors (bortezomib); Tyrosine kinases inhibitors (imatinib)
Non-steroidal anti-
inflammatory drugs Diclofenac; Celecoxib; Rofecoxib
Psychotropes Amoxapine; Clozapine; Diazepam; Lormetazepam
Miscellaneous Azathioprine; Carbamazepine; Furosemide; Hydralazine; Isotretinoin; Lenalidomide; Oral contraceptive;
Levonorgestrel/ethynil oestradiol; gestodene/ethynil oestradiol; Propylthiouracil
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useful and appropriate criteria for its diagnosis, Walker and
Cohen proposed five specific diagnostic criteria in 1996 [7].
Thompson and Montarella performed a systematic review
of literature on drug-induced SS and evaluated the degree
of causal relationships in different case reports [4]. In our
case, we used the modified Naranjo criteria to diagnose
drug-induced SS [4]. The modified scale includes 10
criteria: presence of previous conclusive reports; temporary
onset related to drug administration; temporary resolution
of lesions after drug withdrawal or treatment with a specific
antagonist; temporary recurrence of lesions due to drug
readministration; presence of alternative causes (other than
drugs) that could cause the reaction; appearance of lesions
after placebo administration; drug detection in the blood
(or other fluids) at concentrations known to be toxic; role
of drug dosage in the worsening or improvement of the
reaction; history of exposure to the same or similar drugs,
followed by a similar reaction; and confirmation of an
adverse event by any objective evidence [4]. The case
reported here had a causality score of 4 based on the above
criteria (Possible). This score was not higher because no
rechallenge was performed due to the severity of the
symptoms. There were no signs of any inflammatory
disease, neoplasia, or pregnancy. To the best of our know-
ledge, this is the third case of SS caused by isotretinoin
and the second case of SS caused by isotretinoin therapy
for acne vulgaris.
The first case was reported by Gyorfy et al in 2003. They
reported the cases of two children who developed SS due
to isotretinoin administration. However, the children were
administered this drug to prevent neuroblastoma recur-
rence and dysplastic colon re-emergence after bone mar-
row transplantation and not for acne treatment [8].
The other case of isotretinoin-induced SS was reported
by Ammar et al. in 2007 in a 19-year-old man who received
isotretinoin for severe acne vulgaris that was resistant to
standard topical acne treatment. After one week of the
treatment, the patient developed SS. His condition wasimproved by continuing isotretinoin and by initiating
corticosteroids. However, he was diagnosed as having
ulcerative colitis two years later [9].
In drug-induced SS, a pre-existing underlying condition
associated with SS should be excluded. Clinical criteria can
help in distinguishing drug-induced SS from underlying
conditions. Based on the observation made in this case, we
emphasize the importance of evaluating isotretinoin as a
possible, though uncommon, cause of SS and replacing it
with other treatments if its involvement is suspected.
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